| Literature DB >> 25663004 |
Haibo Liu1, Radu M Cadaneanu, Kevin Lai, Baohui Zhang, Lihong Huo, Dong Sun An, Xinmin Li, Michael S Lewis, Isla P Garraway.
Abstract
BACKGROUND: Human fetal prostate buds appear in the 10th gestational week as solid cords, which branch and form lumens in response to androgen 1. Previous in vivo analysis of prostate epithelia isolated from benign prostatectomy specimens indicated that Epcam⁺ CD44⁻ CD49f(Hi) basal cells possess efficient tubule initiation capability relative to other subpopulations 2. Stromal interactions and branching morphogenesis displayed by adult tubule-initiating cells (TIC) are reminiscent of fetal prostate development. In the current study, we evaluated in vivo tubule initiation by human fetal prostate cells and determined expression profiles of fetal and adult epithelial subpopulations in an effort to identify pathways used by TIC.Entities:
Keywords: basal cell; fetal prostate; human prostate epithelial microarray; prostate stem cell; prostate tissue regeneration; prostate tubule initiation
Mesh:
Substances:
Year: 2015 PMID: 25663004 PMCID: PMC4409819 DOI: 10.1002/pros.22959
Source DB: PubMed Journal: Prostate ISSN: 0270-4137 Impact factor: 4.104
Fig 1Fetal prostate tissue is enriched with epithelial cells that display a marker profile similar to putative adult TIC. Immunohistochemical analysis of (A) epithelial cell marker, Epcam, (B) basal markers CK5, P63, and CD44, (C) intermediate marker, CK19, and (D) luminal markers CK8 and AR in human fetal prostate and benign adult prostate tissue specimens (40× magnification).
Fig 2Isolation and sorting of human fetal prostate cells for in vivo analysis and gene expression profiling. A: Schematic diagram demonstrating the approach for isolating prostate cells from fetal tissues for cell sorting and in vivo/in vitro analysis. B: FACS analysis of cells expressing Epcam, CD44, and CD49f collected from pooled dissociated human fetal prostate tissues. Total prostate cells were stained with Epcam-PE, CD44−FITC, and CD49f-APC conjugated antibodies prior to FACS analysis. Epcam+CD44+ cells are gated in order to evaluate CD49f expression within this population. C. H&E stained sections of paraffin-embedded 12-week grafts harvested from SCID-NODIL2γrNULL mice. Epcam−CD44− (n = 4) or Epcam+CD44− (n = 4) cell fractions were combined with hFPS and Matrigel® were implanted subcutaneously into male SCID-NODIL2γrNULL mice. Testosterone was supplemented via pellets inserted subcutaneously. Grafts induced by Epcam+CD44− (FC) fraction demonstrate a basal layer adjacent to the surrounding stroma containing P63+AR− PSA− cells and secretory cells surrounding the lumen with a P63−AR+PSA+ profile. Representative sections from tissue recombinants using fractionated fetal prostate cells are shown at 4× (H&E) and 40× (IHC) magnification.
Fig 3Microarray analysis of functionally and developmentally distinct human prostate epithelial cell fractions. A. Hierarchical clustering of primary prostate cell fractions sorted from fetal or adult tissues. With the exception of the first row, which contains six pooled fetal samples (Fetal samples 1–6 (pooled) FC), each row represents an individual adult cell fraction and each column represents a single gene. On the hierarchical tree on the left side of the diagram, color coded boxes designate each cell population: the red box indicates the pooled FC (Epcam+CD44−CD49fHi), the purple boxes indicate TIC (Epcam+CD44−CD49fHi), green boxes indicate BC (Epcam+CD44+CD49fHi), and blue boxes indicate LC (Epcam+CD44−CD49fLo). Relative gene expressions are represented with red (higher-level expression), blue (lower level expression), and grey (no change). B. Principal component analysis of fetal and adult prostate cell fractions. Analysis of 19 samples resulted in four relatively distinct groups correlating with antigenic profiles of each cell fraction from adult and fetal tissues.
SC Versus PC + LC
| Probeset ID | Gene symbol | Gene name | Fold difference | |
|---|---|---|---|---|
| 1552487_a_at | BNC1 | basonuclin 1 | 6.99301 | 7.36E-08 |
| 229160_at | MUM1L1 | melanoma associated antigen (mutated) 1-like 1 | 6.51144 | 0.000554755 |
| 228293_at | DEPDC7 | DEP domain containing 7 | 6.44196 | 4.59E-07 |
| 201141_at | GPNMB | glycoprotein (transmembrane) nmb | 5.83103 | 1.80E-06 |
| 230127_at | – | – | 5.6681 | 2.21E-08 |
| 229290_at | DAPL1 | death associated protein-like 1 | 5.51367 | 2.27E-05 |
| 204580_at | MMP12 | matrix metallopeptidase 12 (macrophage elastase) | 5.28229 | 4.12E-06 |
| 205828_at | MMP3 | matrixmetallopeptidase 3 (stromelysin 1, progelatinase) | 5.09891 | 7.07E-05 |
| 204135_at | FILIP1L | filamin A interacting protein 1-like | 4.89582 | 1.36E-05 |
| 1554966_a_at | FILIP1L | filamin A interacting protein 1-like | 4.81849 | 1.34E-05 |
| 241382_at | PCP4L1 | Purkinje cell protein 4 like 1 | 4.79516 | 4.75E-06 |
| 220431_at | TMPRSS11E | transmembrane protease, serine 11E | 4.59135 | 2.10E-05 |
| 240353_s_at | C12orf54 | chromosome 12 open reading frame 54 | 4.54448 | 1.86E-07 |
| 1556793_a_at | FAM83C | family with sequence similarity 83, member C | 4.41239 | 3.58E-06 |
| 209596_at | MXRA5 | matrix-remodelling associated 5 | 4.40538 | 9.87E-09 |
| 226755_at | LOC642587 | NPC-A-5 | 4.30913 | 8.65E-07 |
| 206030_at | ASPA | aspartoacylase | 4.16302 | 4.10E-08 |
| 236220_at | – | – | 4.15706 | 1.45E-05 |
| 233537_at | KRTAP3-1 | keratin associated protein 3-1 | 4.12838 | 2.61E-06 |
| 210809_s_at | POSTN | periostin, osteoblast specific factor | 4.00728 | 1.80E-05 |
| 238956_at | LOC100506781 | hypothetical LOC100506781 | 3.98049 | 0.000165459 |
| 240354_at | C12orf54 | chromosome 12 open reading frame 54 | 3.93021 | 8.45E-06 |
| 212977_at | CXCR7 | chemokine (C-X-C motif) receptor 7 | 3.9302 | 0.000267768 |
| 222484_s_at | CXCL14 | chemokine (C-X-C motif) ligand 14 | 3.9208 | 8.33E-08 |
| 231478_at | PDE4C | phosphodiesterase 4C, cAMP-specific | 3.89515 | 0.000397385 |
| 210096_at | CYP4B1 | cytochrome P450, family 4, subfamily B, polypeptide 1 | 3.76787 | 9.31E-05 |
| 234700_s_at | RNASE7 | ribonuclease, RNase A family, 7 | 3.75572 | 2.82E-06 |
| 219995_s_at | ZNF750 | zinc finger protein 750 | 3.73172 | 0.000370509 |
| 233488_at | RNASE7 | ribonuclease, RNase A family, 7 | 3.69884 | 2.60E-07 |
| 1554333_at | DNAJA4 | DnaJ (Hsp40) homolog, subfamily A, member 4 | 3.67408 | 0.00706654 |
| 214974_x_at | CXCL5 | chemokine (C-X-C motif) ligand 5 | −7.51277 | 0.00489703 |
| 227253_at | CP | ceruloplasmin (ferroxidase) | −6.56691 | 1.09E-07 |
| 202018_s_at | LTF | lactotransferrin | −5.95036 | 0.00041685 |
| 226067_at | C20orf114 | chromosome 20 open reading frame 114 | −5.86084 | 2.28E-06 |
| 204846_at | CP | ceruloplasmin (ferroxidase) | −5.6248 | 2.85E-07 |
| 226147_s_at | PIGR | polymeric immunoglobulin receptor | −5.60813 | 0.000503421 |
| 202376_at | SERPINA3 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), membe | −5.5329 | 3.00E-05 |
| 206392_s_at | RARRES1 | retinoic acid receptor responder (tazarotene induced) 1 | −5.45155 | 0.000770649 |
| 219795_at | SLC6A14 | solute carrier family 6 (amino acid transporter), member 14 | −5.448 | 7.24E-05 |
| 209813_x_at | TARP | TCR gamma alternate reading frame protein | −5.28045 | 2.05E-05 |
| 1558034_s_at | CP | ceruloplasmin (ferroxidase) | −5.05921 | 6.79E-10 |
| 206391_at | RARRES1 | retinoic acid receptor responder (tazarotene induced) 1 | −5.02589 | 0.00013709 |
| 216920_s_at | TARP /// TRGC2 | TCR gamma alternate reading frame protein /// T cell receptor gamma constant 2 | −4.95076 | 8.60E-05 |
| 215806_x_at | TARP /// TRGC2 | TCR gamma alternate reading frame protein /// T cell receptor gamma constant 2 | −4.88084 | 6.83E-05 |
| 205922_at | VNN2 | vanin 2 | −4.84074 | 7.05E-06 |
| 202357_s_at | CFB | complement factor B | −4.83501 | 0.00015103 |
| 215101_s_at | CXCL5 | chemokine (C-X-C motif) ligand 5 | −4.80431 | 0.00109869 |
| 205860_x_at | FOLH1 | folate hydrolase (prostate-specific membrane antigen) 1 | −4.70062 | 1.60E-05 |
| 216623_x_at | TOX3 | TOX high mobility group box family member 3 | −4.64709 | 3.19E-05 |
| 202833_s_at | SERPINA1 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), membe | −4.58774 | 0.000671618 |
| 223721_s_at | DNAJC12 | DnaJ (Hsp40) homolog, subfamily C, member 12 | −4.51425 | 9.57E-08 |
| 230378_at | SCGB3A1 | secretoglobin, family 3A, member 1 | −4.48192 | 1.77E-05 |
| 228143_at | CP | ceruloplasmin (ferroxidase) | −4.37586 | 1.28E-07 |
| 215363_x_at | FOLH1 | folate hydrolase (prostate-specific membrane antigen) 1 | −4.37522 | 1.15E-05 |
| 221872_at | RARRES1 | retinoic acid receptor responder (tazarotene induced) 1 | −4.3391 | 0.0022526 |
| 204124_at | SLC34A2 | solute carrier family 34 (sodium phosphate), member 2 | −4.25842 | 1.65E-06 |
| 214774_x_at | TOX3 | TOX high mobility group box family member 3 | −4.23689 | 2.67E-05 |
| 229659_s_at | – | – | −4.17158 | 4.41E-06 |
| 235229_at | – | – | −4.16726 | 1.55E-05 |
| 209854_s_at | KLK2 | kallikrein-related peptidase 2 | −4.16369 | 0.00329434 |
Fig 4Validation of select genes differentially expressed among prostate epithelial cell fractions. A: Differential expression of the basal marker P63 and luminal markers AR and PSA are demonstrated among the four prostate epithelial populations analyzed (FC—red dot, LC—blue dots, BC—green dots, and TIC—purple dots) in the Affymetrix Gene Chip Human U133 PLUS 2.0 Array analysis. B: RNA was isolated from fractionated cells for evaluation via Quantitative RT-PCR. All reactions were performed in triplicate with a minimum of three unique patient specimens. Black columns represent Unfractionated cells (UC), blue columns represent Epcam+CD44−CD49fLo luminal cells (LC), green columns represent Epcam+CD44+CD49fHi basal cells (BC), and purple columns represent Epcam+CD44−CD49fHi tubule-initiating cells (TIC).
Fig 5Gene Ontology analysis of differentially expressed genes between fractionated prostate cells. The top 10 significantly enriched gene ontologies are presented (A: TIC vs. BC; B: TIC vs. LC).